# Correction: Impact of bictegravir/emtricitabine/tenofovir alafenamide on health-related quality of life and economic outcomes in HIV care: Substudy of the BIC-NOW clinical trial

**Authors:** Sergio Sequera-Arquelladas, María J. Vivancos, David Vinuesa, Antonio Collado, Ignacio De Los Santos, Patricia Sorni, Noemi Cabello-Clotet, Marta Montero, Carlos Ramos Font, Alberto Terron, Maria José Galindo, Onofre Martinez, Pablo Ryan, Mohamed Omar-Mohamed, Helena Albendín-Iglesias, Rosario Javier, Alberto Romero, Coral García Vallecillos, Miguel Ángel Calleja, Carmen Hidalgo-Tenorio

PMC · DOI: 10.1371/journal.pone.0341486 · PLOS One · 2026-01-20

## Full-text entities

- **Chemicals:** bictegravir/emtricitabine/tenofovir alafenamide (MESH:C000654125)
- **Species:** Human immunodeficiency virus 1 (no rank) [taxon 11676]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12818613/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC12818613/full.md

---
Source: https://tomesphere.com/paper/PMC12818613